Abstract 622P
Background
CCL26 is widely found in various tissues of the human body and mainly acts on eosinophils. However, its role in tumors remains unclear. In this study, we aimed to investigate the role of CCL26 in pan-cancer.
Methods
Data were downloaded from University of California Santa Cruz (UCSC) Xena and The Cancer Genome Atlas (TCGA). The expression of CCL26 was investigated in TCGA_GTEx, TCGA and TCGA paired samples, respectively. Subsequently, Kaplan-Meier analyses were performed on 33 TCGA tumors, and clinical correlation and one-way Cox regression analyses were performed on tumors in which CCL26 affected prognosis. In addition, we selected more than 500 representative tumors of renal clear cell carcinoma (KIRC) to construct a nomogram model to confirm the prognostic value of CCL26 in the tumors. In addition, CCL26 there was an association with immune cell infiltration. Mechanistically, we performed functional enrichment analysis to explore potential signaling pathways in which CCL26 may be involved.
Results
Our study found that CCL26 expression was significantly up-regulated in 20 tumors and down-regulated in 6. High expression of CCL26 was associated with shorter overall survival (OS) in adrenocortical carcinoma (ACC), bladder uroepithelial carcinoma (BLCA), renal clear cell carcinoma (KIRC), papillary renal cell carcinoma (KIRP), and mesothelioma (MESO). CCL26 had high predictive accuracy (AUC > 0.9) for five cancers, including cholangiocarcinoma (CHOL; AUC = 0.952, CI: 0.890-0=1.000), renal smoky cell carcinoma (KICH; AUC = 0.928, CI: 0.875- 0.981), lung squamous cell carcinoma (LUSC; AUC = 0.928, CI: 0.905-0.951), skin melanoma (SKCM; AUC = 0.936, CI: NA-NA), thymoma (THYM; AUC = 0.933, CI: 0.829-1.000). -1.000).
Conclusions
CCL26 may serve as a potential prognostic biomarker and a promising target for cancer immunotherapy. It is also associated with clinical outcomes and immune microenvironment in a variety of tumors, and may influence tumor development by regulating signaling pathways of stem cell pluripotency and immune-related pathways.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract